Information Provided By:
Fly News Breaks for October 10, 2019
PRQR
Oct 10, 2019 | 14:55 EDT
Citi analyst Yigal Nochomovitz raised his price target on ProQR Therapeutics to $40 from $34, stating that he disagree's with the market's initial take on the company's updated data on sepofarsen. Given his view that the 12-month data validate the treatment benefits observed at 3 months, Nochomovitz increased his odds on the success for sepofarsen in patients with Leber's congenital amaurosis 10 to 70% from 50% and keeps his Buy rating on the stock. In afternoon trading, ProQR shares are down 26c, or 4%, to $5.95.
News For PRQR From the Last 2 Days
PRQR
PRQR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.